Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05019885 · ClinicalTrials.gov registry record · Phase 2
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
A Phase 2 study of Drug Resistant Epilepsy and Refractory Epilepsy, sponsored by Madeline Fields.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT05019885: Recruiting Phase 2 study of Drug Resistant Epilepsy and Refractory Epilepsy, sponsored by Madeline Fields.
NCT05019885 is a Phase 2 study of Drug Resistant Epilepsy and Refractory Epilepsy that is actively recruiting participants, run by Madeline Fields. The registered enrollment target is 8 participants, below the 35-participant average among 6 other Drug Resistant Epilepsy trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05019885, a Phase 2 study of Drug Resistant Epilepsy and Refractory Epilepsy, is actively recruiting participants, sponsored by Madeline Fields.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous anesthetic dosages are used to treat unrelenting seizures known as status epilepticus in comatose patients. Ketamine in subanesthetic doses has not been tried as a treatment for medication resistant seizures in the outpatient setting. This study would like to examine the effectiveness of subanesthetic ketamine in outpatients who suffer from drug resistant epilepsy.
Primary Outcome
50% seizure reduction during the 2 week period of active treatment
Conditions Studied
Interventions
- DRUG Ketamine Hydrochloride
Study Locations (1)
New York
- Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-08-26 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
What NCT05019885 shows while recruiting
NCT05019885 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 35-participant average among 6 other Drug Resistant Epilepsy trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Drug Resistant Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Ketamine Hydrochloride is the first listed.
NCT05019885 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05019885 about?
NCT05019885 is a clinical study titled "The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy". Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous anesthetic dosages are used to tre...
What is the current status of trial NCT05019885?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-08-26. Estimated completion is 2026-03.
What conditions does trial NCT05019885 study?
This clinical trial studies the following conditions: Drug Resistant Epilepsy, Refractory Epilepsy, Medically Refractory Epilepsy.
What interventions are being tested in trial NCT05019885?
The interventions under investigation include: Ketamine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05019885?
This trial is sponsored by Madeline Fields, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05019885 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Resistant Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Intensity Focused Ultrasound Epilepsy: A Pilot Trial
RECRUITING · NA
-
Infrared Photobiomodulation in Humans With Epilepsy
RECRUITING · NA
-
Goals for Epilepsy Clinic Visits Trial
RECRUITING · NA
-
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
RECRUITING · Phase 1
-
Novel Helmet Design in Patients With Seizures
COMPLETED · NA
-
Electrophysiologic Studies of Cognition in Epilepsy Patients
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI